Cited by 251Medication Adherence and ComplianceBreast Cancer Treatment StudiesCancer survivorship and care

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Adherence to Endocrine Therapy for Breast Cancer

Chlebowski, Rowan T., Geller, Michelle L.·2006·Oncology

Open this paper in CoChat — free account

Abstract

Purpose: Despite the demonstrated efficacy of long-duration adjuvant tamoxifen and aromatase inhibitor use in breast cancer management, information on adherence to such therapy is limited. Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings. Methods: A systematic search of the PubMed database, augmented by a review of manuscript references and conference proceedings, commonly identified adherence reports in clinical trials but identified only 9 adherence reports in clinical practice settings. Results: In adjuvant breast cancer clinical trials with longer (≧4 years) follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23–28% of the study participants. Adherence to aromatase inhibitors did not differ from adherence to tamoxifen in this setting. In breast cancer prevention trials, tamoxifen was prematurely discontinued by 20–46% of the participants. In clinical practice settings, only 2 reports addressed longer-duration (>4 years) adherence to adjuvant tamoxifen use. In these, tamoxifen was prematurely discontinued by 30–50% of the patients. Conclusion: Adherence to prescribed breast cancer hormone therapy has not received concerted attention. Current, albeit limited, evidence suggests long-term hormone therapy adherence may represent an area limiting optimal breast cancer patient treatment.

Integrity signals

Registry

Crossref · 10.1159/000100444

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Adherence to medication.
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759

Flagged first, then by citations

Show all 50 references

Research works printed but not linked: 1

10.1016%2FS0140-6736%2805%2974803-0 · DOI

Sorted by citations

Items 101–200 of 251

Pharmacogenomically actionable medications in a safety net health care system
Carpenter, J. S., Rosenman, M. B., Knisely, M. R., Decker, B. S., Levy, K. D., & Flockhart, D. A. (2016) · SAGE Open Medicine · doi:10.1177/2050312115624333 · Cited by 26
Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study
Sheppard, V. B., Sutton, A. L., Hurtado‐de‐Mendoza, A., He, J., Dahman, B. A., Edmonds, M. C., Hackney, M. H., & Tadesse, M. G. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0604 · Cited by 25
Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors
Thivat, É., Praagh, I. V., Belliere, A., Mouret‐Reynier, M., Kwiatkowski, F., Durando, X., Mahammedi, H., Dillies, A.-F., Chollet, P. J. M., & Chevrier, R. (2012) · Oncology · doi:10.1159/000342087 · Cited by 23
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM
Hadji, P., Kieback, D., Tams, J., Hasenburg, A., & Ziller, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds055 · Cited by 23
Improving outcomes in early-stage breast cancer.
Glück, S., & Mamounas, T. (2010) · PubMed · Cited by 22
Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials
Xie, M., Zhong, Y., Yang, Y., Shen, F., & Yue, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039320 · Cited by 21
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93
Pagani, O., Gelber, S. I., Colleoni, M. A., Price, K. N., & Simoncini, E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2757-x · Cited by 20
Adjuvant therapy use among Appalachian breast cancer survivors
Tan, X., Marshall, V. D., Anderson, R. T., Donohoe, J., Camacho, F., & Balkrishnan, R. (2015) · Medicine · doi:10.1097/md.0000000000001071 · Cited by 20
Impact of physical activity in group versus individual physical activity on fatigue in patients with breast cancer: A pilot study
Desbiens, C., Filion, M., Brien, M.-C., Hogue, J., Laflamme, C., & Lemieux, J. (2017) · The Breast · doi:10.1016/j.breast.2017.06.001 · Cited by 21
Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Sjöström, M., Chang, S. L., Fishbane, N., Davicioni, E., Hartman, L. W., Holmberg, E. C., Feng, F. Y.-C., Speers, C. W., Pierce, L. J., Malmström, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1038 · Cited by 20
Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients
Mao, D., Hachem, H., Chang, H., Dima, D., Dower, J., Wismer, M., Erban, J. K., Freund, K. M., & Parsons, S. K. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05892-z · Cited by 20
Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence
Pourcelot, C., Orillard, É., Nallet, G., Dirand, C., Billion-Rey, F., Barbier, G., Chouk, S., Limat, S., Montcuquet, P., Henriques, J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4676-3 · Cited by 20
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
Henry, N. L., Kim, S., Hays, R. D., Diniz, M. A., Luu, M., Cecchini, R. S., Yothers, G., Rogatko, A., & Ganz, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00910 · Cited by 19
Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)
Bluethmann, S. M., Alfano, C. M., Clapp, J. D., Luta, G., Small, B. J., Hurria, A., Cohen, H. J., Sugarman, S. M., Muss, H. B., Isaacs, C. J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4353-y · Cited by 19
Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data
Sheppard, V. B., He, J., Sutton, A. L., Cromwell, L., Adunlin, G., Salgado, T. M., Tolsma, D., Trout, M., Robinson, B. E., Edmonds, M. C., et al. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.578 · Cited by 19
Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
Montagna, E., Zagami, P., Masiero, M. A., Mazzocco, K., Pravettoni, G., & Munzone, E. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s285768 · Cited by 18
Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer
Myrick, M. E., Schmid, S. M., Kilic, N., & Güth, U. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.619567 · Cited by 18
Palliative Care for Adults Across the Cancer Trajectory: From Diagnosis to End of Life
Brant, J. M. (2010) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2010.08.002 · Cited by 18
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study
Sugita, K., Kawakami, K., Yokokawa, T., Sugisaki, T., Takiguchi, T., Aoyama, T., Suzuki, K., Suenaga, M., Yamaguchi, K., Inoue, A., et al. (2016) · Oncology · doi:10.1159/000448717 · Cited by 18
Breast cancer survivorship symptom management: current perspective and future development
Londen, G. J. V., Beckjord, E. B., Dew, M., Cuijpers, P. J., Tadic, S. D., & Brufsky, A. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.63 · Cited by 18
Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy
Quinn, E. M., Fleming, C., & O’Sullivan, M. J. (2015) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-015-1307-4 · Cited by 17
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution
Hwang, G. S., Paranjpe, R., Opsomer, C., Lu, K., Abajue, U., Abughosh, S., Zaghloul, H. A., & Trivedi, M. V. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.06.004 · Cited by 17
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial
Eadon, M. T., Rosenman, M. B., Zhang, P., Fulton, C. R., Callaghan, J. T., Holmes, A. M., Levy, K. D., Gupta, S. K., Haas, D. M., Vuppalanchi, R., et al. (2023) · The Pharmacogenomics Journal · doi:10.1038/s41397-023-00315-w · Cited by 19
Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma
Mallick, R., Cai, J. X., & Wogen, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.842161 · Cited by 16
Adherence to hormone therapy in women with breast cancer: a quantitative study.
Iacorossi, L., Gambalunga, F., Fabi, A., Giannarelli, D., Facchinetti, G., Piredda, M., & Marinis, M. G. D. (2016) · PubMed · doi:10.7429/pi.2016.692113 · Cited by 17
Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward, J. H. (2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328334ff40 · Cited by 15
Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study
Beko, Z. W., Mengistu, D., Dinegde, N. G., Asefa, T., & Wassie, M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s311445 · Cited by 17
Pain and Menopause Symptoms of Breast Cancer Patients with Adjuvant Hormonal Therapy in Korea: Secondary Analysis
Yi, M., & Hwang, E. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_45_17 · Cited by 15
Selected psychological aspects and medication adherence in oncological patients
Gruszczyńska, M., Bąk‐Sosnowska, M., & Szemik, S. (2019) · Cancer Medicine · doi:10.1002/cam4.2691 · Cited by 14
Discharge to Primary Care for Survivorship Follow-Up: How Are Patients With Early-Stage Breast Cancer Faring?
Railton, C., Lupichuk, S., McCormick, J., Zhong, L., Ko, J. J., Walley, B. A., Joy, A. A., & Giese‐Davis, J. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0091 · Cited by 13
Assessing the Functional Accessibility, Actionability, and Quality of Patient Education Materials from Canadian Cancer Agencies
van Ballegooie, C., Heroux, D., Hoang, P., & Garg, S. (2023) · Current Oncology · doi:10.3390/curroncol30020110 · Cited by 12
Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
Ragusi, M. A. A., van der Velden, B. H. M., van Maaren, M. C., van der Wall, E., van Gils, C. H., Pijnappel, R. M., Gilhuijs, K. G. A., & Elias, S. G. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06550-2 · Cited by 13
Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation
Zhang, G., Jiang, X., Liu, Y., Hao, X., Wang, Y., Yan, X., Yuan, N., Ma, Y., & Ma, M. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2795010 · Cited by 12
Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: Is the risk of treatment worse than the risk of recurrence?
Kauffman, R. P., Young, C., & Castracane, V. D. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111181 · Cited by 13
The Importance of Nonpharmacogenetic Factors in Endocrine Therapy
McCowan, C., & Thompson, A. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.29 · Cited by 11
Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer
Walker, G. A., Kaidar‐Person, O., Kuten, A., & Morgan, D. A. L. (2012) · The Breast · doi:10.1016/j.breast.2012.06.008 · Cited by 11
Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
Gupta, S., Singh, M. K., Vora, A. D., Babu, G., Walia, M., Nautial, V., Saha, R., Smruti, B. K., Sharma, J., Koul, R., et al. (2018) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_122_18 · Cited by 10
Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
Neuner, J. M., Fergestrom, N. M., Pezzin, L. E., Laud, P. W., Ruddy, K. J., & Winn, A. N. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06704-2 · Cited by 13
Barriers and facilitators associated with implementing interventions to support oral anticancer agent adherence in academic and community cancer center settings
Muluneh, B., Muir, M., Collins, J. B., Proco, D., Mackler, E. R., Bryant, A. L., Wood, W. A., Tilkens, M., Reichard, J. S., Foster, M. C., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286630 · Cited by 10
Non-adherence to the Use of Tamoxifen in the First year by the Breast Cancer Patients in an African Population
Oguntola, A., Adeoti, M. L., & Akanbi, O. O. (2011) · TSpace (University of Toronto) · Cited by 10
Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis
Decock, J. V., Hendrickx, W., Vanleeuw, U., Christiaens, Ye, S., & Paridaens, R. (2008) · Breast Cancer Research · doi:10.1186/bcr1915 · Cited by 9
The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients
Taketani, K., Tokunaga, E., Yamashita, N., Tanaka, K., Akiyoshi, S., Okada, S., Ando, K., Kimura, Y., Saeki, H., Oki, E., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0762-7 · Cited by 10
Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race
Ren, Y. T., Black, D. M., Mittendorf, E. A., Liu, P., Li, X., Du, X. L., He, J., Yang, J., Hunt, K. K., & Yi, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110281 · Cited by 9
Social Support, a Mediator in Collaborative Depression Care for Cancer Patients
Oh, H., & Ell, K. (2014) · Research on Social Work Practice · doi:10.1177/1049731514525240 · Cited by 9
Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey
Fallowfield, L. J., Jenkins, V. A., & Coleman, R. E. (2008) · The Breast · doi:10.1016/j.breast.2008.02.009 · Cited by 9
Bevacizumab resistance in breast cancer: are neuropilins the key?
Staton, C. A., Yang, Z., Reed, M., & Brown, N. J. (2008) · Breast Cancer Research · doi:10.1186/bcr1959 · Cited by 8
Prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome
Green, A. R., Burney, C., Granger, C., Paish, E. C., El-Sheikh, S., Rakha, E. A., Powe, D., Macmillan, R. D., Ellis, I. O., & Stylianou, E. (2008) · Breast Cancer Research · doi:10.1186/bcr1947 · Cited by 8
Adherence to Recommended Treatments for Early Invasive Breast Cancer: Decisions of Women Attending Surgeons in the Breast Cancer Audit of Australia and New Zealand
Roder, D. M., de Silva, P., Zorbas, H. M., Webster, F., Kollias, J., Pyke, C., & Campbell, I. D. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.4.1675 · Cited by 7
Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study
Hjorth, C. F., Nielsen, A. S., Sørensen, H. T., Lash, T. L., Damkier, P., Hamilton-Dutoit, S. J., & Cronin-Fenton, D. P. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1537508 · Cited by 7
Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS—method development, validation, comparison of four sample matrices, and proof of concept
Jacobs, C. M., Radosa, J. C., Wagmann, L., Zimmermann, J., Kaya, A. C., Aygün, A., Edel, T., Stotz, L., Ismaeil, M., Solomayer, E., et al. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05244-6 · Cited by 6
Adesão à Terapia Hormonal Adjuvante com Tamoxifeno e Anastrozol utilizando ARMS-12 e MMAS-4
de Botelho, L. O., Sañudo, A., Facina, G., & Wagner, G. A. (2022) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2022v68n2.1960 · Cited by 6
Adherence Rates and Correlates in Long-term Hormonal Therapy
Dunn, J., & Gotay, C. C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00003-4 · Cited by 7
The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence
Neuner, J. M., Fergestrom, N. M., Laud, P. W., Nattinger, A. B., Beyer, K. M. M., Flynn, K. E., & Pezzin, L. E. (2019) · Cancer · doi:10.1002/cncr.32433 · Cited by 6
Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer
Valerio, M. R., Martorana, F., Sanò, M. V., Sambataro, D., Motta, G., Motta, L., Pavone, G., Gebbia, V., & Scandurra, G. (2025) · Biomedicines · doi:10.3390/biomedicines13030546 · Cited by 5
Interactions between BRCA2 protein and the meiosis-specific recombinase DMC1
Thorslund, T., Esashi, F., & West, S. C. (2008) · Breast Cancer Research · doi:10.1186/bcr1887 · Cited by 5
Assessment of angiogenesis in the hyperplasia preinvasive, invasive breast carcinoma sequence
Bluff, J. E., Cross, S. S., Brown, N. J., Reed, M., & Staton, C. A. (2008) · Breast Cancer Research · doi:10.1186/bcr1930 · Cited by 5
Eligibility, Compliance and Persistence of Sequential Therapy with Aromatase Inhibitors following 2–3 Years of Tamoxifen in Endocrine Adjuvant Breast Cancer Therapy
Kilic, N., Myrick, M. E., Schmid, S. M., & Gueth, U. (2011) · Oncology · doi:10.1159/000330768 · Cited by 5
De novo expression of αvβ6 integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression
Allen, M. D., Mulligan, K., Clark, S. E., Hart, I. R., Marshall, J. F., & Jones, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1912 · Cited by 5
Human Factors Engineering: Targeting Systems for Change
Sesto, M. E., Tevaarwerk, A. J., & Wiegmann, D. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1348-7_16 · Cited by 5
Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?
Güth, U., Huang, D. J., Schötzau, A., & Schmid, S. M. (2015) · Oncology · doi:10.1159/000439570 · Cited by 5
Breast cancer and environmental risk factors: an appraisal of the scientific evidence
Kortenkamp, A. (2008) · Breast Cancer Research · doi:10.1186/bcr1929 · Cited by 5
RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours
Cooper, W., Dickinson, R., Dallol, A., Hesson, L. B., Bièche, I., Clark, G., Maher, E. R., Zabarovsky, E., & Latif, F. (2008) · Breast Cancer Research · doi:10.1186/bcr1893 · Cited by 5
CD44 signalling increases cathepsin K and MT1MMP expression to potentiate breast cancer cell invasion through collagen I
Hill, A., McFarlane, S., Johnston, P., & Waugh, D. (2008) · Breast Cancer Research · doi:10.1186/bcr1917 · Cited by 5
Two functionally distinct epithelial progenitors exist within the luminal cell compartment of the mouse mammary gland
Stingl, J., Eaves, C. J., & Watson, C. J. E. (2008) · Breast Cancer Research · doi:10.1186/bcr1886 · Cited by 4
Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study
Elsamany, S. A., Alghanmi, H., Albaradei, A., Hamid, R. M. A., Madi, E., & Ramzan, A. (2022) · The Breast · doi:10.1016/j.breast.2022.01.017 · Cited by 4
Insights Into the Patient Experience of Hormone Therapy for Early Breast Cancer Treatment Using Patient Forum Discussions and Natural Language Processing
Sreenivasan, S., Fang, C., Flood, E. M., Markuzon, N., & Sze, J. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.24.00038 · Cited by 5
Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis
Zhang, Y., Liu, L., Kechang, Z., Xiaowu, W., Huazhen, G., & Ma, Z. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03610-9 · Cited by 4
Long-term Adherence to Hormone Therapy in Medicaid-enrolled Women with Breast Cancer
Wu, J., Stafkey-Mailey, D., & Bennett, C. L. (2012) · Health Outcomes Research in Medicine · doi:10.1016/j.ehrm.2012.10.001 · Cited by 4
Breast and Gynecologic Cancer Prevention in Low-Resource Countries
Bosu, W. K., Cornelison, T. L., & Heckman‐Stoddard, B. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-1876-4_9 · Cited by 4
Health inequalities in breast cancer screening
Tollitt, J., Jain, A., & Astley, S. (2008) · Breast Cancer Research · doi:10.1186/bcr1941 · Cited by 5
A novel role for C-terminal binding proteins in the regulation of mitotic fidelity in breast cancer cells
Bergman, L., Birts, C. N., Darley, M., Gabrielli, B. G., & Blaydes, J. P. (2008) · Breast Cancer Research · doi:10.1186/bcr1892 · Cited by 4
Inhibitor of apoptosis proteins as a therapeutic target in breast cancer
Foster, F. M., Bundred, N. J., & Streuli, C. H. (2008) · Breast Cancer Research · doi:10.1186/bcr1897 · Cited by 4
Design and implementation of a risk-adapted, longitudinal, theory-driven medication adherence intervention: A protocol for a multi-phasic, hybrid effectiveness-implementation trial
Muluneh, B., Upchurch, M., Belayneh, B., Mackler, E. R., Bryant, A. L., Wood, W. A., Boynton, M. H., Wheeler, S. B., Zullig, L. L., & Lafata, J. E. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.02.006 · Cited by 3
Adherence with capecitabine: A population-based analysis based on prescription refill data
Kovacic, L., de Haan, N., de Lemos, M. L., Schaff, K., & Walisser, S. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216676631 · Cited by 3
Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study
Khobrani, A., Alatawi, Y. M., Bajnaid, E., Alemam, O., Osman, A., Attash, L. B., Jaffal, M., Al-Ghanmi, M. A., Alharbi, A. S., & Alnuhait, M. A. (2022) · Cureus · doi:10.7759/cureus.24780 · Cited by 3
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
Moyad, M. A., & Scholz, M. C. (2014) · Research and Reports in Urology · doi:10.2147/rru.s63136 · Cited by 3
Arthralgies, effets secondaires des inhibiteurs de l’aromatase: fréquence, signification et conséquences
Lesur, A., & Barlier, C. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2180-7 · Cited by 3
Homeopathy service in an NHS hospital breast cancer clinic: outcome study
Hughes, S., Smith, A., & Relton, C. (2008) · Breast Cancer Research · doi:10.1186/bcr1977 · Cited by 3
Inhibition of apoptosis by Notch signalling in breast epithelial cells
Meurette, O., Stylianou, S., Collu, G. M., Gilmore, A. P., & Brennan, K. R. (2008) · Breast Cancer Research · doi:10.1186/bcr1904 · Cited by 3
Lineage commitment in mammary epithelium is regulated by type 2 cytokines and Stat6
Khaled, W., Nicholson, S., Baxter, F., Sprigg, N. S., Stingl, J., McKenzie, A., & Watson, C. J. E. (2008) · Breast Cancer Research · doi:10.1186/bcr1888 · Cited by 3
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Williams, L. A., Yücel, E., Cortes, J. E., & Cleeland, C. S. (2013) · Clinical Investigation · doi:10.4155/cli.13.108 · Cited by 3
Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial
Ho, V., Pasquet, R., Luo, S., Chen, G., Goss, P. E., Tu, D., Lazarus, P. J., Richardson, H., & on behalf of the MAP3 Investigators (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05812-1 · Cited by 3
Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
Pieve, C. D., Iley, J., Perkins, A., & Missailidis, S. (2008) · Breast Cancer Research · doi:10.1186/bcr1946 · Cited by 3
Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity
Stone, A., Jones, H. S., Giles, M. G., Gee, J. M. W., & Nicholson, R. I. (2008) · Breast Cancer Research · doi:10.1186/bcr1925 · Cited by 3
Strahlentherapie nach brusterhaltender Therapie
Ataseven, B., EIERMANN, W., Molls, M., & Pigorsch, S. U. (2010) · Der Gynäkologe · doi:10.1007/s00129-010-2642-1 · Cited by 2
Sticking to the script: Breast cancer patients’ decision making regarding oral endocrine therapy
Wheeler, S. B., Roberts, M. C., Waters, A. R., Bloom, D. L., Peppercorn, J. M., Golin, C. E., & Reeder-Hayes, K. E. (2024) · Patient Education and Counseling · doi:10.1016/j.pec.2024.108349 · Cited by 2
AI-based big data analysis of user-generated content to understand adherence in oral hormone receptor-positive advanced breast cancer treatment: A literature review and patient-centered approach using natural language processing
Scholz, S., Winkler, C., & Niescken, S. (2024) · Journal of Digital Health · doi:10.55976/jdh.32024126917-34 · Cited by 2
Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer
Chumsri, S., Pai, T., Ma, Y., Li, Z., Gil, A., Moreno‐Aspitia, A., Colón‐Otero, G., Pogue–Geile, K. L., Rasgoti, P., Paik, S., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7015 · Cited by 2
Ninety Days of Preoperative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy: Primary Results from the Preoperative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER) Trial
Millard, T. A., Turkheimer, L. M., Petroni, G. R., Brighton, D., Meneveau, M. O., Obidike, P. C., McGuire, K. P., & Showalter, S. L. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17861-1 · Cited by 2
Chemotherapy for the Older Adult with Cancer
Mohile, S. G., Nagovskiy, N., & Balducci, L. (2009) · Springer eBooks · doi:10.1007/978-0-387-89070-8_9 · Cited by 2
Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization
Dennison, G. J., Holly, J., McIntosh, J., Winters, Z., & Perks, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr1924 · Cited by 2
Considerations for payers in managing hormone receptor-positive advanced breast cancer
Reimers, & Chitre, M. M. (2014) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s57214 · Cited by 2
Suppression of the NF-κB cofactor Bcl3 inhibits mammary epithelial cell apoptosis and, in breast tumours, correlates with poor prognosis
Wakefield, A., Piggott, L., Croston, D., Jiang, W. G., & Clarkson, R. W. E. (2008) · Breast Cancer Research · doi:10.1186/bcr1884 · Cited by 2
One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy
Henry, N. L., & Stearns, V. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1206-3 · Cited by 2
Activation of TGF-beta signalling in breast cancer metastatic cells
Giampieri, S., & Sahai, E. A. (2008) · Breast Cancer Research · doi:10.1186/bcr1880 · Cited by 2
Urinary and serum biomarkers of phytoestrogen exposure are not associated with breast cancer risk in the European Prospective into Cancer Norfolk study
Ward, H. A., Chapelais, G., Kuhnle, G., Luben, R., Khaw, K., & Bingham, S. A. (2008) · Breast Cancer Research · doi:10.1186/bcr1939 · Cited by 2
Chemotherapy in the elderly: are their needs being met?
Lichtman, S. M. (2009) · Therapy · doi:10.2217/thy.09.72 · Cited by 2
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., et al. (2019) · Breast Care · doi:10.1159/000495469 · Cited by 1
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women
Lee, A. Y., Lyons, A. T., Makris, V., Kamaraju, S., Stolley, M. R., Neuner, J. M., & Flynn, K. E. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08463-w · Cited by 2
The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence
Neuner, J. M., Stolley, M. R., Kamaraju, S., Tiegs, J., Sparapani, R., Makris, V., & Flynn, K. E. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07513-5 · Cited by 1

Authors: Chlebowski, R. T., & Geller, M. L.
Affiliations: The Lundquist Institute (US)
ORCID: Chlebowski, Rowan T.
Venue: Oncology
Publisher: S. Karger AG
Published: 2006
Volume: 71
Issue: 1-2
Pages: 1-9
ISSN: 0030-2414 (ISSN-L)
1423-0232
DOI: 10.1159/000100444
OpenAlex: W1540562253
Cited by: 251
References: 50
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 9 · 2014: 21 · 2013: 14 · 2012: 22
FWCI: 3.00
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords: medication adherence, breast cancer, adjuvant endocrine therapy, tamoxifen, aromatase inhibitors, premature discontinuation, Breast Cancer Prevention Trial
MeSH terms: Administration, Oral, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Patient Compliance, Tamoxifen, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adherence to Endocrine Therapy for Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks